Pipeline Overview
Pioneering ALK-Specific Immuno-Therapies to Redefine Treatment for Resistant Cancers
Strengths
What sets our science apart
ALKemist Bio is built around a unique scientific opportunity: the selective targeting of the ALK oncogene. Our approach is grounded in a strong biological and immunological rationale:
ALK is an oncogene: Strong addiction of tumor cells to ALK signaling for growth and survival
Spontaneous immunogenicity observed in human patients
Selective and high ALK expression by tumor cells
Immunogenicity of ALK peptides –CD8+and CD4+
Restricted and low ALK expression in normal tissues
Anti-tumor activity -synergy with TKIs and ICB
High expression of MHC-I molecules by tumor cells
Identification of immunogenic human ALK peptides led to the discovery of ALK-specific TCRs
With a clear mechanism of action, high therapeutic selectivity, and strong biological rationale, ALKemist Bio’s pipeline holds the potential not only to address urgent unmet clinical needs, but also to deliver a scalable and differentiated asset in the fast-growing field of precision immuno-oncology.